SIDGIDDI, S.; RANGANATHAN, U.; GAUTAM, A. DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 1, n. 3.1, p. s46, 2017. DOI: 10.25251/skin.1.supp.45. Disponível em: https://jofskin.org/index.php/skin/article/view/199. Acesso em: 3 jul. 2024.